Main Hero Image
About Us Icon

PMZ 1620 : Neurovascular diseases


  • A blockbuster biotechnology product that induces production of new neurons and new blood vessels in affected regions of the brain.
  • Potential global market size of more than $18 billion.
  • Intravenous administration of PMZ-1620 induces neurogenesis and angiogenesis in the ischemic but not in the non-ischemic hemisphere of the brain.
  • Potential use of PMZ-1620 ranging from neurodegenerative diseases, brain injuries to cerebrovascular accidents.
  • Efficacy of PMZ-1620 has been demonstrated in animal models of Alzheimer’s disease and cerebral ischemia.
  • Chemistry, manufacturing and controls for PMZ-1620 are well established.
  • US patent titled “Methods for treatment of stroke or cerebrovascular accidents using IRL-1620” US Patent No. 8,623,823 has been issued.
  • China patent titled “Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin B receptor agonist” China patent No. ZL 2008 8 0113425.6 has been issued.
  • Patents in other countries are pending.
  • PMZ-1620 has been safely used in humans for other indications (NCT00613691; NCT01741155; NCT01773785 and CTRI/2013/07/003854).
  • Clinical stage – in preparation for human efficacy (Phase II) studies.
  • Link to publications